ethyl glycinate methacrylate | 31978-16-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: ethyl glycinate methacrylate
• 英文别名: Methacrylaminoessigsaeureethylester；ethyl glycinate methacrylamide；N-methacryloyl-glycine ethyl ester；N-Methacryloyl-glycin-aethylester；Ethyl 2-(2-methylprop-2-enoylamino)acetate
• CAS: 31978-16-2
• 化学式: C₈H₁₃NO₃
• 分子量: 171.196
• InChiKey: PCYVXVDHBBWWPC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl glycinate methacrylate 在 一水合肼 作用下， 以 甲醇 为溶剂， 生成 methacryloyl glycine hydrazide
  参考文献：
  名称：

  IN VIVO STEALTH NANOPARTICLE

  摘要：

  提供的是一种分子印迹聚合物，通过一种新机制能够获得隐身特性。根据本发明的分子印迹聚合物，其具有由血浆蛋白在其上分子印迹的血浆蛋白识别位点，并含有源自生物相容单体的成分，是用于体内血管内输送的隐身纳米颗粒。作为血浆蛋白，白蛋白是首选。根据本发明，当携带药物时，该体内隐身纳米颗粒可用作药物传递系统的药物。

  公开号：

  US20170319485A1
• 作为产物：
  描述：

  2-胺基乙酸乙酯 、 甲基丙烯酰氯 生成 ethyl glycinate methacrylate
  参考文献：
  名称：

  Petrowa et al., Zhurnal Fizicheskoj Khimii, 1959, vol. 33, p. 1246,1247

  摘要：

  DOI：

文献信息

• In vivo stealth nanoparticle
  申请人：Takeuchi Toshifumi

  公开号：US10471011B2

  公开（公告）日：2019-11-12

  Provided is a molecular imprint polymer that is capable of acquiring stealth properties through a new mechanism. The molecular imprint polymer according to the present invention, which has a plasma protein recognition sites molecularly imprinted by a plasma protein thereon and contains a constituent derived from a biocompatible monomer, is an in vivo stealth nanoparticle to be used in intravascular delivery. As the plasma protein, albumin is preferred. When carrying a drug thereon, the in vivo stealth nanoparticle according to the present invention is usable as a drug for drug delivery system.

  本发明提供了一种能够通过新机制获得隐形特性的分子印迹聚合物。本发明的分子印记聚合物具有由血浆蛋白分子印记在其上的血浆蛋白识别位点，并含有由生物相容性单体衍生的成分，是一种可用于血管内给药的体内隐形纳米粒子。作为血浆蛋白，首选白蛋白。当携带药物时，根据本发明的体内隐形纳米粒子可用作药物输送系统。
• Ioffe; Kusnezow, Zhurnal Obshchei Khimii, 1959, vol. 29, p. 3804,3805,3806;engl.Ausg.S.3766
  作者：Ioffe、Kusnezow

  DOI：——

  日期：——
• Acid-Activatable Prodrug Nanogels for Efficient Intracellular Doxorubicin Release
  作者：Fuxing Zhan、Wei Chen、Zhongjuan Wang、Wentao Lu、Ru Cheng、Chao Deng、Fenghua Meng、Haiyan Liu、Zhiyuan Zhong

  DOI：10.1021/bm200876x

  日期：2011.10.10

  Endosomal pH-activatable doxorubicin (DOX) prodrug nanogels were designed, prepared, and investigated for triggered intracellular drug release in cancer cells. DOX prodrugs with drug grafting contents of 3.9, 5.7, and 11.7 wt % (denoted as prodrugs 1, 2, and 3, respectively) were conveniently obtained by sequential treatment of poly(ethylene glycol)-b-poly(2-hydroxyethyl methacrylate-co-ethyl glycinate methacrylamide) (PEG-b-P(HEMA-co-EGMA)) copolymers with hydrazine and doxorubicin hydrochloride. Notably, prodrugs 1, 2, and 3 formed monodispersed nanogels with average sizes of 114.4, 75.3, and 66.3 nm, respectively, in phosphate buffer (PB, 10 mM, pH 7.4). The in vitro release results showed that DOX was released rapidly and nearly quantitatively from DOX prodrug nanogels at endosomal pH and 37 degrees C in 48 h, whereas only a minor amount (ca. 20% or less) of drug was released at pH 7.4 under otherwise the same conditions. Confocal laser scanning microscope (CLSM) observations revealed that DOX prodrug nanogels delivered and released DOX into the cytosols as well as cell nuclei of RAW 264.7 cells following 24 h incubation. MTT assays demonstrated that prodrug 3 had pronounced cytotoxic effects to tumor cells following 72 h incubation with IC50 data determined to be 2.0 and 3.4 mu g DOX equiv/mL for RAW 264.7 and MCF-7 tumor cells, respectively. The corresponding polymer carrier, PEG-b-P(HEMA-co-GMA-hydrazide), was shown to be nontoxic up to a tested concentration of 1.32 mg/mL. These endosomal pH-activatable DOX prodrug nanogels uniquely combining features of water-soluble macromolecular prodrugs and nanogels offer a promising platform for targeted cancer therapy.